Cover Image
Market Research Report

Global Sarcoma Therapeutics Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 762864
Published Content info 114 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Sarcoma Therapeutics Market 2019-2023
Published: December 14, 2018 Content info: 114 Pages
Description

About this market

The advent of regenerative medicine to drive growth in the market. One of the most advanced and extensively researched treatment methods is regenerative medicines, including gene therapy. In gene therapy, the mutated gene is taken from the patient and is modified genetically in laboratory and administered back into the patient. Technavio's analysts have predicted that the sarcoma therapeutics market will register a CAGR of more than 8% by 2023.

Market Overview

Launch of novel drugs

The market is currently dominated by the sales of GLEEVEC for the treatment of sarcomas. The launch of novel drugs is expected to be one of the major growth drivers in the market.

High treatment costs

The cost of therapeutics is usually high as most of the drugs that are currently approved in the market are large molecules. These drugs are expensive due to the complex manufacturing process of biologicals and high R&D costs.

For the detailed list of factors that will drive and challenge the growth of the sarcoma therapeutics market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Bayer and Eisai the competitive environment is quite intense. Factors such as the advent of regenerative medicine and the launch of novel drugs, will provide considerable growth opportunities to sarcoma therapeutics manufactures. Bayer, Eisai, Eli Lilly, Johnson & Johnson, and Novartis are some of the major companies covered in this report.

Table of Contents
Product Code: IRTNTR30495

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Soft tissue sarcoma - Market size and forecast 2018-2023
  • Osteosarcoma - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer
  • Eisai
  • Eli Lilly
  • Johnson & Johnson
  • Novartis

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

PART 16: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global oncology therapeutics market
  • Exhibit 02: Segments of global oncology therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Global sarcoma therapeutics market pipeline: Overview
  • Exhibit 18: Type - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: Soft tissue sarcoma - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Soft tissue sarcoma - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Osteosarcoma - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Osteosarcoma - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by type
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Key leading countries
  • Exhibit 35: Market opportunity
  • Exhibit 36: Impact of drivers and challenges
  • Exhibit 37: Vendor landscape
  • Exhibit 38: Landscape disruption
  • Exhibit 39: Vendors covered
  • Exhibit 40: Vendor classification
  • Exhibit 41: Market positioning of vendors
  • Exhibit 42: Bayer - Vendor overview
  • Exhibit 43: Bayer - Business segments
  • Exhibit 44: Bayer - Organizational developments
  • Exhibit 45: Bayer - Geographic focus
  • Exhibit 46: Bayer - Segment focus
  • Exhibit 47: Bayer - Key offerings
  • Exhibit 48: Bayer - Key customers
  • Exhibit 49: Eisai - Vendor overview
  • Exhibit 50: Eisai - Business segments
  • Exhibit 51: Eisai - Organizational developments
  • Exhibit 52: Eisai - Geographic focus
  • Exhibit 53: Eisai - Segment focus
  • Exhibit 54: Eisai - Key offerings
  • Exhibit 55: Eisai - Key customers
  • Exhibit 56: Eli Lilly - Vendor overview
  • Exhibit 57: Eli Lilly - Business segments
  • Exhibit 58: Eli Lilly - Organizational developments
  • Exhibit 59: Eli Lilly - Geographic focus
  • Exhibit 60: Eli Lilly - Segment focus
  • Exhibit 61: Eli Lilly - Key offerings
  • Exhibit 62: Eli Lilly - Key customers
  • Exhibit 63: Johnson & Johnson - Vendor overview
  • Exhibit 64: Johnson & Johnson - Business segments
  • Exhibit 65: Johnson & Johnson - Organizational developments
  • Exhibit 66: Johnson & Johnson - Geographic focus
  • Exhibit 67: Johnson & Johnson - Segment focus
  • Exhibit 68: Johnson & Johnson - Key offerings
  • Exhibit 69: Johnson & Johnson - Key customers
  • Exhibit 70: Novartis - Vendor overview
  • Exhibit 71: Novartis - Business segments
  • Exhibit 72: Novartis - Organizational developments
  • Exhibit 73: Novartis - Geographic focus
  • Exhibit 74: Novartis - Segment focus
  • Exhibit 75: Novartis - Key offerings
  • Exhibit 76: Novartis - Key customers
Back to Top